← 返回

针对包膜蛋白的人 T 细胞白血病病毒特异性抗体依赖性细胞介导的细胞毒性(ADCC)检测方法的开发与优化

英文原题:Development and optimization of human T-cell leukemia virus-specific antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed to the envelope protein.

查看英文原题

Development and optimization of human T-cell leukemia virus-specific antibody-dependent cell-mediated cytotoxicity (ADCC) assay directed to the envelope protein.

PubMed 2025/03/28(内容时间) J Virol Q1 · IF 4.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

据估计,全球有1000万至2000万人感染了δ逆转录病毒人T细胞白血病病毒1型(HTLV-1)。尽管大多数感染者保持无症状,但部分人会进展为致命且使人衰弱的疾病——成人T细胞白血病/淋巴瘤(ATLL)或HTLV相关脊髓病/热带痉挛性截瘫(HAM/TSP),或发展为大量其他炎症性疾病。

此外,HTLV-1感染与免疫抑制和寿命缩短相关。尽管中和抗体的保护作用已被提出,但非中和性抗体依赖性细胞介导的细胞毒性(ADCC)的作用仍不清楚,主要因为尚未建立检测这种反应的试验方法。

在此,我们开发了一种基于高通量流式细胞术的检测系统,用于测量HTLV-1包膜特异性ADCC。我们使用稳定表达绿色荧光蛋白GFP的NK 细胞抗性T淋巴母细胞样细胞系,构建了表达HTLV-1包膜蛋白的靶细胞系,并使用单克隆抗体以及来自HTLV感染或未感染个体的血浆样本,验证了该试验的特异性和敏感性。

我们在HTLV-1感染人类的样本中检测到高ADCC活性。在实验感染猕猴的血浆中,测量了ADCC活性,并观察到ADCC活性与HTLV-1包膜抗体滴度之间的相关性。

此外,我们观察到ADCC滴度随时间显著增加;随着HTLV-1感染的持续,产生更高的ADCC反应,可能影响疾病结局。HTLV-1感染猕猴中的ADCC滴度也与FLT3LG、IL-17F、CD4+ T细胞和淋巴细胞呈正相关,但与单核细胞频率和经典单核细胞频率呈负相关。

总之,这些发现详细描述了一个细胞系的建立,该细胞系使得HTLV特异性ADCC检测方法的开发成为可能,该方法可用于大型临床研究以及涉及人类或非人灵长类动物的研究。重要性 该方法测量人类T细胞白血病病毒(HTLV)特异性包膜抗体依赖性细胞介导的细胞毒性反应,为研究包膜特异性结合抗体在HTLV感染免疫控制和发病机制中的作用提供了关键工具,并可能有助于指导治疗性和预防性疫苗方法的开发。

展开英文摘要原文

An estimated 10-20 million people worldwide are infected with the deltaretrovirus human T-cell leukemia virus type 1 (HTLV-1). Although most infected individuals remain asymptomatic, some progress to develop the fatal and debilitating disease adult T-cell leukemia/lymphoma (ATLL) or HTLV-associated myelopathy/tropical spastic paraparesis (HAM/TSP) or develop a plethora of other inflammatory disorders.

In addition, HTLV-1 infection is associated with immunosuppression and a shorter lifespan. Although a protective role for neutralizing antibodies has been suggested, the role of non-neutralizing antibody-dependent cell-mediated cytotoxicity (ADCC) remains unclear, largely because an assay to measure this response has not been established.

Here, we developed a high-throughput flow cytometry-based assay system to measure HTLV-1 envelope-specific ADCC.

We used a natural killer cell-resistant T-lymphoblastoid cell line stably expressing the green fluorescent protein GFP to construct a target cell line expressing HTLV-1 envelope protein and using monoclonal antibodies and plasma samples from HTLV-infected or uninfected individuals, validating the specificity and sensitivity of the assay.

We detected high ADCC activity in samples from HTLV-1-infected humans. In the plasma of experimentally infected macaques, ADCC activity was measured and a correlation between ADCC activity and HTLV-1 envelope antibody titers was observed.

Further, we observed a significant increase in ADCC titer over time; as HTLV-1 infection persists, a higher ADCC response is generated, potentially influencing disease outcome. ADCC titer in HTLV-1-infected macaques also positively correlated with FLT3LG, IL-17F, CD4 + T cells, and lymphocytes but negatively correlated with monocyte frequency and classical monocyte frequency.

In conclusion, these findings detail the generation of a cell line that enabled development of an HTLV-specific ADCC assay, which can be employed in large clinical studies as well as research involving humans or non-human primates.

IMPORTANCEThis approach measures human T-cell leukemia virus (HTLV)-specific envelope antibody-dependent cell-mediated cytotoxicity responses, provides a critical tool to investigate the role of envelope-specific binding antibodies in the immune control of HTLV infection and pathogenesis, and may help guide the development of both therapeutic and preventative vaccine approaches.

论文信息

作者
Pise-Masison CA、Rahman MA、Masison DC、Gutowska A、Moles R、Bissa M、Sarkis S、Schifanella L
单位
Animal Models and Retroviral Vaccines Section, Basic Research Laboratory, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.United States
文献类型
非美国政府资助研究
期刊
Journal of virology2025 May 20
原文标识
PubMed 40152593 · DOI 10.1128/jvi.02268-24